GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Cyclically Adjusted Price-to-FCF

Assembly Biosciences (FRA:V7B) Cyclically Adjusted Price-to-FCF : (As of Sep. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Assembly Biosciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Assembly Biosciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Cyclically Adjusted Price-to-FCF Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Assembly Biosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Assembly Biosciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Assembly Biosciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Cyclically Adjusted Price-to-FCF falls into.



Assembly Biosciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Assembly Biosciences's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Assembly Biosciences's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-2.818/132.5538*132.5538
=-2.818

Current CPI (Jun. 2024) = 132.5538.

Assembly Biosciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -4.378 100.428 -5.778
201412 -3.396 99.070 -4.544
201503 -3.677 99.621 -4.893
201506 -2.747 100.684 -3.617
201509 -3.222 100.392 -4.254
201512 -3.491 99.792 -4.637
201603 -5.765 100.470 -7.606
201606 -4.198 101.688 -5.472
201609 -4.903 101.861 -6.380
201612 -7.362 101.863 -9.580
201703 22.706 102.862 29.260
201706 -7.611 103.349 -9.762
201709 -6.354 104.136 -8.088
201712 -5.209 104.011 -6.638
201803 -7.474 105.290 -9.409
201806 -8.050 106.317 -10.037
201809 -6.913 106.507 -8.604
201812 -7.006 105.998 -8.761
201903 -10.520 107.251 -13.002
201906 -8.687 108.070 -10.655
201909 -7.820 108.329 -9.569
201912 -7.997 108.420 -9.777
202003 -7.828 108.902 -9.528
202006 -6.720 108.767 -8.190
202009 3.054 109.815 3.686
202012 -7.455 109.897 -8.992
202103 -9.252 111.754 -10.974
202106 -5.066 114.631 -5.858
202109 -4.227 115.734 -4.841
202112 -4.574 117.630 -5.154
202203 -6.227 121.301 -6.805
202206 -4.205 125.017 -4.459
202209 -4.959 125.227 -5.249
202212 -4.472 125.222 -4.734
202303 -5.147 127.348 -5.357
202306 -2.888 128.729 -2.974
202309 -2.963 129.860 -3.024
202312 12.690 129.419 12.997
202403 -3.084 131.776 -3.102
202406 -2.818 132.554 -2.818

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Assembly Biosciences  (FRA:V7B) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Assembly Biosciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences Headlines

No Headlines